Edition:
United Kingdom

Surmodics Inc (SRDX.OQ)

SRDX.OQ on NASDAQ Stock Exchange Global Select Market

63.09USD
19 Oct 2018
Change (% chg)

$-1.85 (-2.85%)
Prev Close
$64.94
Open
$65.43
Day's High
$65.70
Day's Low
$63.09
Volume
9,888
Avg. Vol
34,366
52-wk High
$82.35
52-wk Low
$25.00

Latest Key Developments (Source: Significant Developments)

Surmodics Acquires Thrombectomy Technology Assets
Monday, 14 May 2018 

May 14 (Reuters) - Surmodics Inc ::SURMODICS ACQUIRES THROMBECTOMY TECHNOLOGY ASSETS FROM EMBOLITECH, STRENGTHENING PERIPHERAL VASCULAR WHOLE-PRODUCT SOLUTIONS PORTFOLIO.SURMODICS INC - UNDER AGREEMENT, SURMODICS WILL PAY $5 MILLION UP FRONT, AND ADDITIONAL AMOUNTS RELATED TO VARIOUS REGULATORY MILESTONES.SURMODICS INC - ANTICIPATES RECORDING A $0.49 PER SHARE CHARGE TO EARNINGS IN Q3 OF FISCAL 2018.SURMODICS - ANTICIPATES RECORDING CHARGE IN Q3 RELATED TO IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE AND DEAL COSTS ASSOCIATED WITH DEAL.  Full Article

Surmodics Reports Q2 Non-GAAP EPS $0.07
Wednesday, 2 May 2018 

May 2 (Reuters) - Surmodics Inc ::SURMODICS REPORTS SECOND QUARTER FISCAL 2018 RESULTS, INCREASES FISCAL 2018 GUIDANCE.SURMODICS INC <<>> Q2 NON-GAAP SHR $0.07.SURMODICS INC <<>> Q2 GAAP SHR $0.11.SURMODICS INC <<>> SEES FY 2018 REVENUE $75 MLN TO $79 MLN.SURMODICS INC <<>> Q2 SHR VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.SURMODICS INC <<>> Q2 REVENUE $19.1 MLN VS I/B/E/S VIEW $17.7 MLN.SURMODICS INC - NOW EXPECTS DILUTED LOSS IN RANGE OF $0.20 TO $0.35 PER SHARE FOR 2018.  Full Article

Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation Catheter
Monday, 23 Apr 2018 

April 23 (Reuters) - Surmodics Inc ::SURMODICS ANNOUNCES FDA CLEARANCE OF A NEW .018” LOW-PROFILE PTA BALLOON DILATION CATHETER.SURMODICS INC - SURMODICS EXPECTS TO MAKE NEW .018" LOW-PROFILE PTA BALLOON DILATION CATHETER AVAILABLE FOR DISTRIBUTION IN COMING MONTHS.  Full Article

Surmodics Q4 gaap earnings per share $0.03
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Surmodics Inc :Surmodics reports fourth quarter fiscal 2017 results and provides fiscal 2018 guidance.Q4 non-gaap earnings per share $0.18.Q4 gaap earnings per share $0.03.Q4 revenue $20.1 million versus i/b/e/s view $17.3 million.Q4 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Sees fy 2018 non-gaap loss per share $0.16 to $0.41.Sees fy 2018 loss per share $0.50 to $0.75.Sees fy 2018 revenue $72 million to $75 million.Fy2018 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Surmodics Acquires Thrombectomy Technology Assets

* SURMODICS ACQUIRES THROMBECTOMY TECHNOLOGY ASSETS FROM EMBOLITECH, STRENGTHENING PERIPHERAL VASCULAR WHOLE-PRODUCT SOLUTIONS PORTFOLIO